

# Bibliography

- 1 UK, C. R. *Cancer risk statistics*, <<https://www.cancerresearchuk.org/health-professional/cancer-statistics/risk>>
- 2 UK, C. R. *Cancer survival statistics*, <<https://www.cancerresearchuk.org/health-professional/cancer-statistics/survival>>
- 3 Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* **22**, 7265-7279, doi:10.1038/sj.onc.1206933 (2003).
- 4 Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nature Reviews Cancer* **6**, 789-802, doi:10.1038/nrc1977 (2006).
- 5 Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. *Nature Reviews Cancer* **3**, 330-338, doi:10.1038/nrc1074 (2003).
- 6 Chabner, B. A. & Roberts, T. G. Chemotherapy and the war on cancer. *Nature Reviews Cancer* **5**, 65-72, doi:10.1038/nrc1529 (2005).
- 7 Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. *Nature Reviews Cancer* **6**, 714-727, doi:10.1038/nrc1913 (2006).
- 8 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
- 9 Baselga, J. The EGFR as a target for anticancer therapy--focus on cetuximab. *European journal of cancer (Oxford, England : 1990)* **37 Suppl 4**, S16-22, doi:10.1016/s0959-8049(01)00233-7 (2001).
- 10 Carter, P. *et al.* Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proceedings of the National Academy of Sciences* **89**, 4285, doi:10.1073/pnas.89.10.4285 (1992).
- 11 Souers, A. J. *et al.* ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature medicine* **19**, 202, doi:10.1038/nm.3048 (2013).
- 12 Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* **3**, 391-400, doi:10.1038/nrd1381 (2004).
- 13 Duvic, M. & Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. *Expert opinion on investigational drugs* **16**, 1111-1120, doi:10.1517/13543784.16.7.1111 (2007).
- 14 Hodi, F. S. *et al.* Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. *Proc Natl Acad Sci U S A* **100**, 4712-4717, doi:10.1073/pnas.0830997100 (2003).
- 15 Phan, G. Q. *et al.* Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* **100**, 8372-8377, doi:10.1073/pnas.1533209100 (2003).
- 16 Mullard, A. FDA approves landmark tissue-agnostic cancer drug. *Nature Reviews Drug Discovery* **18**, 7, doi:10.1038/nrd.2018.226 (2018).
- 17 Chial, H. Proto-oncogenes to oncogenes to cancer. *Nature Education* **1**, 33 (2008).
- 18 Davies, H. *et al.* Mutations of the BRAF gene in human cancer. *Nature* **417**, 949-954, doi:10.1038/nature00766 (2002).
- 19 Shimizu, K. *et al.* Three human transforming genes are related to the viral ras oncogenes. *Proc Natl Acad Sci U S A* **80**, 2112-2116, doi:10.1073/pnas.80.8.2112 (1983).

- 20 Chial, H. Tumor suppressor (TS) genes and the two-hit hypothesis. *Nature Education* **1**, 177 (2008).
- 21 Oren, M. p53: the ultimate tumor suppressor gene? *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **6**, 3169-3176, doi:10.1096/fasebj.6.13.1397838 (1992).
- 22 Murphree, A. L. & Benedict, W. F. Retinoblastoma: clues to human oncogenesis. *Science* **223**, 1028-1033, doi:10.1126/science.6320372 (1984).
- 23 Morris, L. G. & Chan, T. A. Therapeutic targeting of tumor suppressor genes. *Cancer* **121**, 1357-1368, doi:10.1002/cncr.29140 (2015).
- 24 Guo, X. E., Ngo, B., Modrek, A. S. & Lee, W.-H. Targeting tumor suppressor networks for cancer therapeutics. *Curr Drug Targets* **15**, 2-16 (2014).
- 25 Zheng, L. & Lee, W.-H. The Retinoblastoma Gene: A Prototypic and Multifunctional Tumor Suppressor. *Experimental Cell Research* **264**, 2-18, doi:10.1006/excr.2000.5129 (2001).
- 26 Du, W. & Searle, J. S. The rb pathway and cancer therapeutics. *Curr Drug Targets* **10**, 581-589 (2009).
- 27 Yamaguchi, T. *et al.* Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor. *Cancer Science* **98**, 1809-1816, doi:10.1111/j.1349-7006.2007.00604.x (2007).
- 28 Saidi, S. A., Holland, C. M., Charnock-Jones, D. S. & Smith, S. K. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. *Mol Cancer* **5**, 13-13, doi:10.1186/1476-4598-5-13 (2006).
- 29 Das, P. M. & Singal, R. DNA methylation and cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **22**, 4632-4642, doi:10.1200/jco.2004.07.151 (2004).
- 30 Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* **5**, 769-784, doi:10.1038/nrd2133 (2006).
- 31 Morris, L. G. T. & Chan, T. A. Therapeutic targeting of tumor suppressor genes. *Cancer* **121**, 1357-1368, doi:10.1002/cncr.29140 (2015).
- 32 Hartman, J. L., Garvik, B. & Hartwell, L. Principles for the Buffering of Genetic Variation. *Science* **291**, 1001, doi:10.1126/science.1056072 (2001).
- 33 Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. *Science* **278**, 1064-1068, doi:10.1126/science.278.5340.1064 (1997).
- 34 Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? *Nature Reviews Clinical Oncology* **15**, 564-576, doi:10.1038/s41571-018-0055-6 (2018).
- 35 Kaelin, W. G. The Concept of Synthetic Lethality in the Context of Anticancer Therapy. *Nature Reviews Cancer* **5**, 689-698, doi:10.1038/nrc1691 (2005).
- 36 Kroll, E. S., Hyland, K. M., Hieter, P. & Li, J. J. Establishing Genetic Interactions by a Synthetic Dosage Lethality Phenotype. *Genetics* **143**, 95 (1996).
- 37 Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov* **13**, 828-851, doi:10.1038/nrd4389 (2014).
- 38 Muller, F. L. *et al.* Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature* **488**, 337, doi:10.1038/nature11331 (2012).
- 39 Muller, F. L., Aquilanti, E. A. & DePinho, R. A. Collateral Lethality: A new therapeutic strategy in oncology. *Trends Cancer* **1**, 161-173, doi:10.1016/j.trecan.2015.10.002 (2015).

- 40 Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. *Nature* **461**, 1071-1078, doi:10.1038/nature08467 (2009).
- 41 Li, G.-M. Mechanisms and functions of DNA mismatch repair. *Cell Research* **18**, 85-98, doi:10.1038/cr.2007.115 (2008).
- 42 Krokan, H. E. & Bjørås, M. Base excision repair. *Cold Spring Harb Perspect Biol* **5**, a012583-a012583, doi:10.1101/cshperspect.a012583 (2013).
- 43 de Laat, W. L., Jaspers, N. G. & Hoeijmakers, J. H. Molecular mechanism of nucleotide excision repair. *Genes & development* **13**, 768-785, doi:10.1101/gad.13.7.768 (1999).
- 44 Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu Rev Biochem* **79**, 181-211, doi:10.1146/annurev.biochem.052308.093131 (2010).
- 45 San Filippo, J., Sung, P. & Klein, H. Mechanism of Eukaryotic Homologous Recombination. *Annu Rev Biochem* **77**, 229-257, doi:10.1146/annurev.biochem.77.061306.125255 (2008).
- 46 Bryant, H. E. *et al.* Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913-917, doi:10.1038/nature03443 (2005).
- 47 Farmer, H. *et al.* Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917-921, doi:10.1038/nature03445 (2005).
- 48 Administration, U. S. F. D. *Niraparib (ZEJULA)*, <<https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula>> (2017).
- 49 Administration, U. S. F. D. *Rucaparib*, <<https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib>> (2016).
- 50 Administration, U. S. F. D. *FDA approves olaparib for germline BRCA-mutated metastatic breast cancer*, <<https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer>> (2018).
- 51 Administration, U. S. F. D. *FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer*, <<https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer>> (2018).
- 52 AstraZeneca. *LYNPARZA™ approved by the US Food and Drug Administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations*, <<https://www.astrazeneca-us.com/media/press-releases/2014/lynparza-approved-by-the-us-fda-20141219.html#>> (2014).
- 53 Goffeau, A. *et al.* Life with 6000 genes. *Science* **274**, 546, 563-547, doi:10.1126/science.274.5287.546 (1996).
- 54 Hanson, P. K. *Saccharomyces cerevisiae: A Unicellular Model Genetic Organism of Enduring Importance. Current Protocols Essential Laboratory Techniques* **16**, e21, doi:10.1002/cpet.21 (2018).
- 55 Yan Tong, A. H. & Boone, C. in *Yeast Protocol* (ed Wei Xiao) 171-191 (Humana Press, 2006).
- 56 Pan, X. *et al.* A DNA Integrity Network in the Yeast *Saccharomyces cerevisiae*. *Cell* **124**, 1069-1081, doi:10.1016/j.cell.2005.12.036 (2006).
- 57 Pan, X. *et al.* A Robust Toolkit for Functional Profiling of the Yeast Genome. *Molecular Cell* **16**, 487-496, doi:10.1016/j.molcel.2004.09.035 (2004).
- 58 Decourty, L. *et al.* Linking functionally related genes by sensitive and quantitative characterization of genetic interaction profiles. *Proceedings of the National Academy of Sciences* **105**, 5821, doi:10.1073/pnas.0710533105 (2008).

- 59 Tong, A. H. Y. *et al.* Global Mapping of the Yeast Genetic Interaction Network. *Science* **303**, 808, doi:10.1126/science.1091317 (2004).
- 60 Kachroo, A. H. *et al.* Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. *Science (New York, N.Y.)* **348**, 921-925, doi:10.1126/science.aaa0769 (2015).
- 61 Srivas, R. *et al.* A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. *Molecular cell* **63**, 514-525, doi:10.1016/j.molcel.2016.06.022 (2016).
- 62 Ryan, C. J., Bajrami, I. & Lord, C. J. Synthetic Lethality and Cancer - Penetrance as the Major Barrier. *Trends Cancer* **4**, 671-683, doi:10.1016/j.trecan.2018.08.003 (2018).
- 63 Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer cell* **3**, 285-296 (2003).
- 64 Torrance, C. J., Agrawal, V., Vogelstein, B. & Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. *Nat Biotechnol* **19**, 940-945, doi:10.1038/nbt1001-940 (2001).
- 65 Turcotte, S. *et al.* A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. *Cancer cell* **14**, 90-102, doi:10.1016/j.ccr.2008.06.004 (2008).
- 66 Ward, T. A., McHugh, P. J. & Durant, S. T. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes. *PloS one* **12**, e0179278-e0179278, doi:10.1371/journal.pone.0179278 (2017).
- 67 Reddy, A. S. & Zhang, S. Polypharmacology: drug discovery for the future. *Expert Rev Clin Pharmacol* **6**, 41-47, doi:10.1586/ecp.12.74 (2013).
- 68 MacDonald, M. L. *et al.* Identifying off-target effects and hidden phenotypes of drugs in human cells. *Nature Chemical Biology* **2**, 329-337, doi:10.1038/nchembio790 (2006).
- 69 Fire, A. *et al.* Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806-811, doi:10.1038/35888 (1998).
- 70 Silva, J., Chang, K., Hannon, G. J. & Rivas, F. V. RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. *Oncogene* **23**, 8401-8409, doi:10.1038/sj.onc.1208176 (2004).
- 71 Paddison, P. J. & Hannon, G. J. RNA interference: the new somatic cell genetics? *Cancer cell* **2**, 17-23, doi:10.1016/S1535-6108(02)00092-2 (2002).
- 72 Campeau, E. & Gobeil, S. RNA interference in mammals: behind the screen. *Briefings in Functional Genomics* **10**, 215-226, doi:10.1093/bfpg/elr018 (2011).
- 73 Boettcher, M. & Hoheisel, J. D. Pooled RNAi Screens - Technical and Biological Aspects. *Curr Genomics* **11**, 162-167, doi:10.2174/138920210791110988 (2010).
- 74 McDonald, E. R., 3rd *et al.* Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. *Cell* **170**, 577-592.e510, doi:10.1016/j.cell.2017.07.005 (2017).
- 75 Tsherniak, A. *et al.* Defining a Cancer Dependency Map. *Cell* **170**, 564-576.e516, doi:10.1016/j.cell.2017.06.010 (2017).
- 76 Williams, S. P., Barthorpe, A. S., Lightfoot, H., Garnett, M. J. & McDermott, U. High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. *Scientific Data* **4**, 170139, doi:10.1038/sdata.2017.139 (2017).
- 77 Semizarov, D. *et al.* Specificity of short interfering RNA determined through gene expression signatures. *Proc Natl Acad Sci U S A* **100**, 6347-6352, doi:10.1073/pnas.1131959100 (2003).
- 78 Jackson, A. L. *et al.* Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol* **21**, 635-637, doi:10.1038/nbt831 (2003).

- 79 Mohr, S. E., Smith, J. A., Shamu, C. E., Neumüller, R. A. & Perrimon, N. RNAi screening comes of age: improved techniques and complementary approaches. *Nat Rev Mol Cell Biol* **15**, 591-600, doi:10.1038/nrm3860 (2014).
- 80 Boettcher, M. & McManus, M. T. Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. *Molecular cell* **58**, 575-585, doi:10.1016/j.molcel.2015.04.028 (2015).
- 81 Ishino, Y., Shinagawa, H., Makino, K., Amemura, M. & Nakata, A. Nucleotide sequence of the *iap* gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *Journal of Bacteriology* **169**, 5429, doi:10.1128/jb.169.12.5429-5433.1987 (1987).
- 82 Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J. & Soria, E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. *Journal of molecular evolution* **60**, 174-182, doi:10.1007/s00239-004-0046-3 (2005).
- 83 Pourcel, C., Salvignol, G. & Vergnaud, G. CRISPR elements in *Yersinia pestis* acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. *Microbiology (Reading, England)* **151**, 653-663, doi:10.1099/mic.0.27437-0 (2005).
- 84 Barrangou, R. *et al.* CRISPR provides acquired resistance against viruses in prokaryotes. *Science* **315**, 1709-1712, doi:10.1126/science.1138140 (2007).
- 85 Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I. & Koonin, E. V. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. *Biology direct* **1**, 7, doi:10.1186/1745-6150-1-7 (2006).
- 86 Lander, E. S. The Heroes of CRISPR. *Cell* **164**, 18-28, doi:10.1016/j.cell.2015.12.041 (2016).
- 87 Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819-823, doi:10.1126/science.1231143 (2013).
- 88 Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823-826, doi:10.1126/science.1232033 (2013).
- 89 Le Rhun, A., Escalera-Maurer, A., Bratovič, M. & Charpentier, E. CRISPR-Cas in *Streptococcus pyogenes*. *RNA Biol* **16**, 380-389, doi:10.1080/15476286.2019.1582974 (2019).
- 90 Brouns, S. J. *et al.* Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* **321**, 960-964, doi:10.1126/science.1159689 (2008).
- 91 Deltcheva, E. *et al.* CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* **471**, 602, doi:10.1038/nature09886 (2011).
- 92 Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816-821, doi:10.1126/science.1225829 (2012).
- 93 Garneau, J. E. *et al.* The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature* **468**, 67, doi:10.1038/nature09523 (2010).
- 94 Chapman, J. R., Taylor, Martin R. G. & Boulton, Simon J. Playing the End Game: DNA Double-Strand Break Repair Pathway Choice. *Molecular Cell* **47**, 497-510, doi:10.1016/j.molcel.2012.07.029 (2012).
- 95 Barrangou, R. & Doudna, J. A. Applications of CRISPR technologies in research and beyond. *Nature Biotechnology* **34**, 933, doi:10.1038/nbt.3659 (2016).
- 96 Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173-1183, doi:10.1016/j.cell.2013.02.022 (2013).
- 97 Gilbert, L. A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442-451, doi:10.1016/j.cell.2013.06.044 (2013).

- 98 Hu, J. H. *et al.* Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature* **556**, 57, doi:10.1038/nature26155 (2018).
- 99 Ma, D. *et al.* Engineer chimeric Cas9 to expand PAM recognition based on evolutionary information. *Nature Communications* **10**, 560, doi:10.1038/s41467-019-08395-8 (2019).
- 100 Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR–Cas technologies and applications. *Nature Reviews Molecular Cell Biology* **20**, 490-507, doi:10.1038/s41580-019-0131-5 (2019).
- 101 Guitart, J. R., Johnson, J. L. & Chien, W. W. Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology. *Journal of Investigative Dermatology* **136**, e87-e93, doi:10.1016/j.jid.2016.06.007 (2016).
- 102 Kampmann, M. CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine. *ACS Chem Biol* **13**, 406-416, doi:10.1021/acscchembio.7b00657 (2018).
- 103 Metzakopian, E. *et al.* Enhancing the genome editing toolbox: genome wide CRISPR arrayed libraries. *Scientific reports* **7**, 2244, doi:10.1038/s41598-017-01766-5 (2017).
- 104 Shalem, O. *et al.* Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. *Science* **343**, 84, doi:10.1126/science.1247005 (2014).
- 105 Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic Screens in Human Cells Using the CRISPR-Cas9 System. *Science* **343**, 80, doi:10.1126/science.1246981 (2014).
- 106 Hart, T. *et al.* Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. *G3: Genes|Genomes|Genetics* **7**, 2719, doi:10.1534/g3.117.041277 (2017).
- 107 Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. *Nat Methods* **11**, 783-784, doi:10.1038/nmeth.3047 (2014).
- 108 Park, R. J. *et al.* A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. *Nature genetics* **49**, 193-203, doi:10.1038/ng.3741 (2017).
- 109 Behan, F. M. *et al.* Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. *Nature* **568**, 511-516, doi:10.1038/s41586-019-1103-9 (2019).
- 110 Tzelepis, K. *et al.* A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. *Cell Rep* **17**, 1193-1205, doi:10.1016/j.celrep.2016.09.079 (2016).
- 111 Morgens, D. W. *et al.* Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. *Nature communications* **8**, 15178-15178, doi:10.1038/ncomms15178 (2017).
- 112 Allen, F. *et al.* JACKS: joint analysis of CRISPR/Cas9 knockout screens. *Genome Research*, doi:10.1101/gr.238923.118 (2019).
- 113 Diaz, A. A., Qin, H., Ramalho-Santos, M. & Song, J. S. HiTSelect: a comprehensive tool for high-complexity-pooled screen analysis. *Nucleic Acids Res* **43**, e16-e16, doi:10.1093/nar/gku1197 (2015).
- 114 Hart, T. & Moffat, J. BAGEL: a computational framework for identifying essential genes from pooled library screens. *BMC Bioinformatics* **17**, 164, doi:10.1186/s12859-016-1015-8 (2016).
- 115 König, R. *et al.* A probability-based approach for the analysis of large-scale RNAi screens. *Nature Methods* **4**, 847, doi:10.1038/nmeth1089 (2007).
- 116 Li, W. *et al.* MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biology* **15**, 554, doi:10.1186/s13059-014-0554-4 (2014).

- 117 Luo, J. *et al.* A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell* **137**, 835-848, doi:10.1016/j.cell.2009.05.006 (2009).
- 118 Yu, J., Silva, J. & Califano, A. ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. *Bioinformatics (Oxford, England)* **32**, 260-267, doi:10.1093/bioinformatics/btv556 (2016).
- 119 Agrotis, A. & Ketteler, R. A new age in functional genomics using CRISPR/Cas9 in arrayed library screening. *Frontiers in genetics* **6**, 300, doi:10.3389/fgene.2015.00300 (2015).
- 120 Cui, Y., Xu, J., Cheng, M., Liao, X. & Peng, S. Review of CRISPR/Cas9 sgRNA Design Tools. *Interdisciplinary sciences, computational life sciences* **10**, 455-465, doi:10.1007/s12539-018-0298-z (2018).
- 121 Wilson, L. O. W., O'Brien, A. R. & Bauer, D. C. The Current State and Future of CRISPR-Cas9 gRNA Design Tools. *Front Pharmacol* **9**, 749-749, doi:10.3389/fphar.2018.00749 (2018).
- 122 Yau, E. H. *et al.* Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. *Cancer Res* **77**, 6330-6339, doi:10.1158/0008-5472.Can-17-2043 (2017).
- 123 Sun, N. *et al.* &em&gt;VHL&lt;/em&gt; Synthetic Lethality Signatures Uncovered by Genotype-specific CRISPR-Cas9 Screens. *bioRxiv*, 588707, doi:10.1101/588707 (2019).
- 124 Wang, T. *et al.* Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras. *Cell* **168**, 890-903.e815, doi:10.1016/j.cell.2017.01.013 (2017).
- 125 Chan, E. M. *et al.* WRN helicase is a synthetic lethal target in microsatellite unstable cancers. *Nature* **568**, 551-556, doi:10.1038/s41586-019-1102-x (2019).
- 126 Wang, C. *et al.* Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. *Oncogene* **38**, 2451-2463, doi:10.1038/s41388-018-0606-4 (2019).
- 127 Adikusuma, F., Pfitzner, C. & Thomas, P. Q. Versatile single-step-assembly CRISPR/Cas9 vectors for dual gRNA expression. *PloS one* **12**, e0187236-e0187236, doi:10.1371/journal.pone.0187236 (2017).
- 128 Han, K. *et al.* Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. *Nat Biotechnol* **35**, 463-474, doi:10.1038/nbt.3834 (2017).
- 129 Shen, J. P. *et al.* Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. *Nat Methods* **14**, 573-576, doi:10.1038/nmeth.4225 (2017).
- 130 Vidigal, J. A. & Ventura, A. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. *Nature Communications* **6**, 8083, doi:10.1038/ncomms9083 (2015).
- 131 Horlbeck, M. A. *et al.* Mapping the Genetic Landscape of Human Cells. *Cell* **174**, 953-967.e922, doi:10.1016/j.cell.2018.06.010 (2018).
- 132 Jacunski, A., Dixon, S. J. & Tatonetti, N. P. Connectivity Homology Enables Inter-Species Network Models of Synthetic Lethality. *PLoS Computational Biology* **11**, e1004506, doi:10.1371/journal.pcbi.1004506 (2015).
- 133 Wu, M. *et al.* In Silico Prediction of Synthetic Lethality by Meta-Analysis of Genetic Interactions, Functions, and Pathways in Yeast and Human Cancer. *Cancer Informatics* **13s3**, CIN.S14026, doi:10.4137/CIN.S14026 (2014).

- 134 Conde-Pueyo, N., Munteanu, A., Solé, R. V. & Rodríguez-Caso, C. Human synthetic lethal inference as potential anti-cancer target gene detection. *BMC Syst Biol* **3**, 116-116, doi:10.1186/1752-0509-3-116 (2009).
- 135 Deshpande, R. *et al.* A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res* **73**, 6128-6136, doi:10.1158/0008-5472.Can-12-3956 (2013).
- 136 Cancer Genome Atlas Research, N. *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nature genetics* **45**, 1113-1120, doi:10.1038/ng.2764 (2013).
- 137 Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. *Genome Research* **22**, 398-406 (2012).
- 138 Etemadmoghadam, D. *et al.* Synthetic lethality between CCNE1 amplification and loss of BRCA1. *Proc Natl Acad Sci U S A* **110**, 19489-19494, doi:10.1073/pnas.1314302110 (2013).
- 139 Jerby-Arnon, L. *et al.* Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality. *Cell* **158**, 1199-1209, doi:10.1016/j.cell.2014.07.027 (2014).
- 140 Wang, W. *et al.* Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. *EMBO J* **15**, 5370-5382 (1996).
- 141 Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E. & Green, M. R. Nucleosome disruption and enhancement of activator binding by a human SWI/SNF complex. *Nature* **370**, 477-481, doi:10.1038/370477a0 (1994).
- 142 Pan, J. *et al.* Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. *Cell systems* **6**, 555-568.e557, doi:10.1016/j.cels.2018.04.011 (2018).
- 143 Michel, B. C. *et al.* A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. *Nature cell biology* **20**, 1410-1420, doi:10.1038/s41556-018-0221-1 (2018).
- 144 Alpsy, A. & Dykhuizen, E. C. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. *The Journal of biological chemistry* **293**, 3892-3903, doi:10.1074/jbc.RA117.001065 (2018).
- 145 Yoo, A. S., Staahl, B. T., Chen, L. & Crabtree, G. R. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. *Nature* **460**, 642-646, doi:10.1038/nature08139 (2009).
- 146 Lessard, J. *et al.* An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* **55**, 201-215, doi:10.1016/j.neuron.2007.06.019 (2007).
- 147 Lickert, H. *et al.* Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. *Nature* **432**, 107-112, doi:10.1038/nature03071 (2004).
- 148 Tuoc, T. C. *et al.* Chromatin regulation by BAF170 controls cerebral cortical size and thickness. *Developmental cell* **25**, 256-269, doi:10.1016/j.devcel.2013.04.005 (2013).
- 149 Ho, L. *et al.* An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. *Proc Natl Acad Sci U S A* **106**, 5181-5186, doi:10.1073/pnas.0812889106 (2009).
- 150 Li, S. *et al.* Genome-wide coactivation analysis of PGC-1alpha identifies BAF60a as a regulator of hepatic lipid metabolism. *Cell metabolism* **8**, 105-117, doi:10.1016/j.cmet.2008.06.013 (2008).



- 151 Meng, Z. X. *et al.* Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation. *Nature medicine* **19**, 640-645, doi:10.1038/nm.3144 (2013).
- 152 Hodges, C., Kirkland, J. G. & Crabtree, G. R. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. *Cold Spring Harb Perspect Med* **6**, a026930, doi:10.1101/cshperspect.a026930 (2016).
- 153 Kadoch, C. *et al.* Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. *Nat Genet* **45**, 592-601, doi:10.1038/ng.2628 (2013).
- 154 Shain, A. H. & Pollack, J. R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. *PLoS One* **8**, e55119, doi:10.1371/journal.pone.0055119 (2013).
- 155 Sandhya, S., Maulik, A., Giri, M. & Singh, M. Domain architecture of BAF250a reveals the ARID and ARM-repeat domains with implication in function and assembly of the BAF remodeling complex. *PLoS One* **13**, e0205267, doi:10.1371/journal.pone.0205267 (2018).
- 156 Li, X. S., Trojer, P., Matsumura, T., Treisman, J. E. & Tanese, N. Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. *Molecular and cellular biology* **30**, 1673-1688, doi:10.1128/mcb.00540-09 (2010).
- 157 Jones, S. *et al.* Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* **330**, 228-231, doi:10.1126/science.1196333 (2010).
- 158 Wiegand, K. C. *et al.* ARID1A mutations in endometriosis-associated ovarian carcinomas. *The New England journal of medicine* **363**, 1532-1543, doi:10.1056/NEJMoa1008433 (2010).
- 159 Kandoth, C. *et al.* Integrated genomic characterization of endometrial carcinoma. *Nature* **497**, 67-73, doi:10.1038/nature12113 (2013).
- 160 Wang, K. *et al.* Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. *Nat Genet* **43**, 1219-1223, doi:10.1038/ng.982 (2011).
- 161 Gui, Y. *et al.* Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet* **43**, 875-878, doi:10.1038/ng.907 (2011).
- 162 Wang, X. *et al.* Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. *Biochem J* **383**, 319-325, doi:10.1042/BJ20040524 (2004).
- 163 Nagl, N. G., Jr., Wang, X., Patsialou, A., Van Scoy, M. & Moran, E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. *EMBO J* **26**, 752-763, doi:10.1038/sj.emboj.7601541 (2007).
- 164 Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **499**, 43-49, doi:10.1038/nature12222 (2013).
- 165 Brownlee, P. M., Chambers, A. L., Cloney, R., Bianchi, A. & Downs, J. A. BAF180 promotes cohesion and prevents genome instability and aneuploidy. *Cell Rep* **6**, 973-981, doi:10.1016/j.celrep.2014.02.012 (2014).
- 166 Niimi, A., Chambers, A. L., Downs, J. A. & Lehmann, A. R. A role for chromatin remodellers in replication of damaged DNA. *Nucleic Acids Res* **40**, 7393-7403, doi:10.1093/nar/gks453 (2012).
- 167 Hodis, E. *et al.* A landscape of driver mutations in melanoma. *Cell* **150**, 251-263, doi:10.1016/j.cell.2012.06.024 (2012).
- 168 Ding, L. *et al.* Clonal architectures and driver mutations in metastatic melanomas. *PLoS One* **9**, e111153, doi:10.1371/journal.pone.0111153 (2014).

- 169 Lee, J. J. *et al.* Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. *Clinical epigenetics* **7**, 59, doi:10.1186/s13148-015-0091-3 (2015).
- 170 Manceau, G. *et al.* Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. *International journal of cancer* **132**, 2217-2221, doi:10.1002/ijc.27900 (2013).
- 171 Li, M. *et al.* Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. *Nat Genet* **43**, 828-829, doi:10.1038/ng.903 (2011).
- 172 Helming, K. C. *et al.* ARID1B is a specific vulnerability in ARID1A-mutant cancers. *Nature medicine* **20**, 251-254, doi:10.1038/nm.3480 (2014).
- 173 Ogiwara, H. *et al.* Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. *Cancer cell* **35**, 177-190.e178, doi:10.1016/j.ccell.2018.12.009 (2019).
- 174 Miller, R. E. *et al.* Synthetic Lethal Targeting of <em>ARID1A</em>-Mutant Ovarian Clear Cell Tumors with Dasatinib. *Molecular Cancer Therapeutics* **15**, 1472, doi:10.1158/1535-7163.MCT-15-0554 (2016).
- 175 Xiao, W., Awadallah, A. & Xin, W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. *International journal of clinical and experimental pathology* **5**, 642-650 (2012).
- 176 Kwan, S. Y. *et al.* Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. *Oncotarget* **7**, 56933-56943, doi:10.18632/oncotarget.10921 (2016).
- 177 Caumanns, J. J. *et al.* Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research* **24**, 3928-3940, doi:10.1158/1078-0432.Ccr-17-3060 (2018).
- 178 Shen, J. *et al.* ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. *Cancer discovery* **5**, 752-767, doi:10.1158/2159-8290.CD-14-0849 (2015).
- 179 Williamson, C. T. *et al.* ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. *Nature Communications* **7**, 13837, doi:10.1038/ncomms13837 (2016).
- 180 Bitler, B. G. *et al.* Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nature medicine* **21**, 231, doi:10.1038/nm.3799 (2015).
- 181 Kim, K. H. *et al.* SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. *Nature medicine* **21**, 1491-1496, doi:10.1038/nm.3968 (2015).
- 182 Januario, T. *et al.* PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors. *Proc Natl Acad Sci U S A* **114**, 12249-12254, doi:10.1073/pnas.1703966114 (2017).
- 183 Fukumoto, T. *et al.* Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. *Cell Reports* **22**, 3393-3400, doi:10.1016/j.celrep.2018.03.019 (2018).
- 184 van der Vlag, J. & Otte, A. P. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. *Nat Genet* **23**, 474-478, doi:10.1038/70602 (1999).
- 185 Bitler, B. G. *et al.* ARID1A-mutated ovarian cancers depend on HDAC6 activity. *Nature cell biology* **19**, 962, doi:10.1038/ncb3582 (2017).
- 186 Hopkins, S. R., McGregor, G. A., Murray, J. M., Downs, J. A. & Savic, V. Novel synthetic lethality screening method identifies TIP60-dependent radiation sensitivity in the absence of BAF180. *DNA Repair* **46**, 47-54, doi:10.1016/j.dnarep.2016.05.030 (2016).

- 187 Xue, Y. *et al.* SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. *Nat Commun* **10**, 557, doi:10.1038/s41467-019-08380-1 (2019).
- 188 Xue, Y. *et al.* CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun* **10**, 558, doi:10.1038/s41467-018-06958-9 (2019).
- 189 Romero, O. A. *et al.* &lt;em&gt;MAX&lt;/em&gt; Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1. *Cancer discovery* **4**, 292, doi:10.1158/2159-8290.CD-13-0799 (2014).
- 190 Lissanu Deribe, Y. *et al.* Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. *Nature medicine* **24**, 1047-1057, doi:10.1038/s41591-018-0019-5 (2018).
- 191 Oike, T. *et al.* A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1. *Cancer Research* **73**, 5508, doi:10.1158/0008-5472.CAN-12-4593 (2013).
- 192 Hoffman, G. R. *et al.* Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. *Proc Natl Acad Sci U S A* **111**, 3128-3133, doi:10.1073/pnas.1316793111 (2014).
- 193 Wang, X. *et al.* Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. *Cancer research* **69**, 8094-8101, doi:10.1158/0008-5472.CAN-09-0733 (2009).
- 194 Jones, S. E. *et al.* ATR Is a Therapeutic Target in Synovial Sarcoma. *Cancer research* **77**, 7014-7026, doi:10.1158/0008-5472.CAN-17-2056 (2017).
- 195 Alimova, I. *et al.* Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. *Neuro Oncol* **15**, 149-160, doi:10.1093/neuonc/nos285 (2013).
- 196 Knutson, S. K. *et al.* Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. *Proc Natl Acad Sci U S A* **110**, 7922-7927, doi:10.1073/pnas.1303800110 (2013).
- 197 Wilson, B. G. *et al.* Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. *Cancer cell* **18**, 316-328, doi:10.1016/j.ccr.2010.09.006 (2010).
- 198 Sun, Y., Jiang, X., Chen, S., Fernandes, N. & Price, B. D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. *Proc Natl Acad Sci U S A* **102**, 13182-13187, doi:10.1073/pnas.0504211102 (2005).
- 199 Fenech, M. *et al.* Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. *Mutagenesis* **26**, 125-132, doi:10.1093/mutage/geq052 (2011).
- 200 Clark, J. *et al.* Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. *Nature Genetics* **7**, 502-508, doi:10.1038/ng0894-502 (1994).
- 201 Kadoch, C. & Crabtree, G. R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. *Cell* **153**, 71-85, doi:10.1016/j.cell.2013.02.036 (2013).
- 202 Versteeg, I. *et al.* Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature* **394**, 203-206, doi:10.1038/28212 (1998).
- 203 Eaton, K. W., Tooke, L. S., Wainwright, L. M., Judkins, A. R. & Biegel, J. A. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. *Pediatric Blood & Cancer* **56**, 7-15, doi:10.1002/pbc.22831 (2011).
- 204 Biegel, J. A. *et al.* Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. *Cancer Res* **59**, 74-79 (1999).

- 205 Hohmann, A. F. *et al.* Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. *Nature Chemical Biology* **12**, 672, doi:10.1038/nchembio.2115 (2016).
- 206 Martin, L. J. *et al.* Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. *Journal of Medicinal Chemistry* **59**, 4462-4475, doi:10.1021/acs.jmedchem.5b01865 (2016).
- 207 Gulati, N., Beguelin, W. & Giulino-Roth, L. Enhancer of zeste homolog 2 (EZH2) inhibitors. *Leukemia & lymphoma* **59**, 1574-1585, doi:10.1080/10428194.2018.1430795 (2018).
- 208 Yee, A. J. *et al.* Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. *The Lancet Oncology* **17**, 1569-1578, doi:10.1016/S1470-2045(16)30375-8 (2016).
- 209 Caumanns, J. J., Wisman, G. B. A., Berns, K., van der Zee, A. G. J. & de Jong, S. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* **1870**, 176-184, doi:10.1016/j.bbcan.2018.07.005 (2018).
- 210 Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663-676, doi:10.1016/j.cell.2006.07.024 (2006).
- 211 Takahashi, K. *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861-872, doi:10.1016/j.cell.2007.11.019 (2007).
- 212 Yu, J. *et al.* Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. *Science* **318**, 1917, doi:10.1126/science.1151526 (2007).
- 213 Cyranoski, D. 'Reprogrammed' stem cells approved to mend human hearts for the first time. *Nature* **557**, 619-620, doi:10.1038/d41586-018-05278-8 (2018).
- 214 Cyranoski, D. 'Reprogrammed' stem cells implanted into patient with Parkinson's disease. *Nature*, doi:doi: 10.1038/d41586-018-07407-9 (2018).
- 215 Cyranoski, D. 'Reprogrammed' stem cells to treat spinal-cord injuries for the first time. *Nature*, doi:doi: 10.1038/d41586-019-00656-2 (2019).
- 216 Hockemeyer, D. *et al.* Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nature biotechnology* **27**, 851-857, doi:10.1038/nbt.1562 (2009).
- 217 Hockemeyer, D. *et al.* Genetic engineering of human pluripotent cells using TALE nucleases. *Nature biotechnology* **29**, 731-734, doi:10.1038/nbt.1927 (2011).
- 218 Santos, D. P., Kiskinis, E., Eggan, K. & Merkle, F. T. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells. *Curr Protoc Stem Cell Biol* **38**, 5B.6.1-5B.6.60, doi:10.1002/cpsc.15 (2016).
- 219 Alateeq, S. *et al.* Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns. *APL Bioengineering* **2**, 046103, doi:10.1063/1.5048625 (2018).
- 220 Shinkuma, S., Guo, Z. & Christiano, A. M. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. *Proceedings of the National Academy of Sciences* **113**, 5676, doi:10.1073/pnas.1512028113 (2016).
- 221 Smith, C. *et al.* Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. *Cell Stem Cell* **15**, 12-13, doi:10.1016/j.stem.2014.06.011 (2014).

- 222 Takayama, K. *et al.* Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system. *Nucleic Acids Res* **45**, 5198-5207, doi:10.1093/nar/gkx130 (2017).
- 223 Tan, E. P., Li, Y., Del Castillo Velasco-Herrera, M., Yusa, K. & Bradley, A. Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells. *genesis* **53**, 225-236, doi:10.1002/dvg.22835 (2015).
- 224 Park, C. Y. *et al.* Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. *Cell Stem Cell* **17**, 213-220, doi:10.1016/j.stem.2015.07.001 (2015).
- 225 Chang, C. W. *et al.* Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. *Cell Rep* **12**, 1668-1677, doi:10.1016/j.celrep.2015.08.013 (2015).
- 226 Li, C. *et al.* Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction. *Scientific reports* **6**, 30422-30422, doi:10.1038/srep30422 (2016).
- 227 Veres, A. *et al.* Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. *Cell Stem Cell* **15**, 27-30, doi:10.1016/j.stem.2014.04.020 (2014).
- 228 Ben Jehuda, R., Shemer, Y. & Binah, O. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9. *Stem Cell Reviews and Reports* **14**, 323-336, doi:10.1007/s12015-018-9811-3 (2018).
- 229 Horii, T., Tamura, D., Morita, S., Kimura, M. & Hatada, I. Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. *International journal of molecular sciences* **14**, 19774-19781, doi:10.3390/ijms141019774 (2013).
- 230 Flynn, R. *et al.* CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. *Experimental hematology* **43**, 838-848.e833, doi:10.1016/j.exphem.2015.06.002 (2015).
- 231 Wang, L. *et al.* CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. *Protein & Cell* **8**, 365-378, doi:10.1007/s13238-017-0397-3 (2017).
- 232 Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. *Nat Rev Drug Discov* **16**, 115-130, doi:10.1038/nrd.2016.245 (2017).
- 233 He, X. *et al.* Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. *Nucleic Acids Res* **44**, e85, doi:10.1093/nar/gkw064 (2016).
- 234 Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol* **31**, 827-832, doi:10.1038/nbt.2647 (2013).
- 235 Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *eLife* **3**, e04766, doi:10.7554/eLife.04766 (2014).
- 236 Zhang, Y. *et al.* Functional genomic screen of human stem cell differentiation reveals pathways involved in neurodevelopment and neurodegeneration. *Proceedings of the National Academy of Sciences* **110**, 12361, doi:10.1073/pnas.1309725110 (2013).
- 237 Chia, N.-Y. *et al.* A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. *Nature* **468**, 316, doi:10.1038/nature09531 (2010).
- 238 Ihry, R. J. *et al.* Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes. *Cell Reports* **27**, 616-630.e616, doi:10.1016/j.celrep.2019.03.043 (2019).

- 239 Mair, B. *et al.* Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies. *Cell Reports* **27**, 599-615.e512, doi:10.1016/j.celrep.2019.02.041 (2019).
- 240 Yilmaz, A., Peretz, M., Aharony, A., Sagi, I. & Benvenisty, N. Defining essential genes for human pluripotent stem cells by CRISPR–Cas9 screening in haploid cells. *Nature cell biology* **20**, 610-619, doi:10.1038/s41556-018-0088-1 (2018).
- 241 Ihry, R. J. *et al.* p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. *Nature medicine* **24**, 939-946, doi:10.1038/s41591-018-0050-6 (2018).
- 242 Wong, C. C. *et al.* Inactivating CUX1 mutations promote tumorigenesis. *Nat Genet* **46**, 33-38, doi:10.1038/ng.2846 (2014).
- 243 Rashid, S. T. *et al.* Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. *The Journal of clinical investigation* **120**, 3127-3136, doi:10.1172/jci43122 (2010).
- 244 Perlmutter, D. H. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in  $\alpha$ -1-antitrypsin deficiency. *Cell Death & Differentiation* **16**, 39-45, doi:10.1038/cdd.2008.103 (2009).
- 245 Yusa, K. *et al.* Targeted gene correction of  $\alpha$ 1-antitrypsin deficiency in induced pluripotent stem cells. *Nature* **478**, 391-394, doi:10.1038/nature10424 (2011).
- 246 Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* **34**, 184-191, doi:10.1038/nbt.3437 (2016).
- 247 Hart, T. *et al.* High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. *Cell* **163**, 1515-1526, doi:10.1016/j.cell.2015.11.015 (2015).
- 248 Paludan, K., Duch, M., Jorgensen, P., Kjeldgaard, N. O. & Pedersen, F. S. Graduated resistance to G418 leads to differential selection of cultured mammalian cells expressing the neo gene. *Gene* **85**, 421-426, doi:10.1016/0378-1119(89)90435-6 (1989).
- 249 Kim, J. H. *et al.* High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. *PLoS One* **6**, e18556, doi:10.1371/journal.pone.0018556 (2011).
- 250 Jang, S. K. *et al.* A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. *J Virol* **62**, 2636-2643 (1988).
- 251 Pelletier, J. & Sonenberg, N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. *Nature* **334**, 320-325, doi:10.1038/334320a0 (1988).
- 252 Mizuguchi, H., Xu, Z., Ishii-Watabe, A., Uchida, E. & Hayakawa, T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. *Molecular therapy : the journal of the American Society of Gene Therapy* **1**, 376-382, doi:10.1006/mthe.2000.0050 (2000).
- 253 Sumarriva Lezama, L. *et al.* An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality. *Histopathology* **73**, 767-776, doi:10.1111/his.13668 (2018).
- 254 Bejjani, B. A. & Shaffer, L. G. Application of array-based comparative genomic hybridization to clinical diagnostics. *J Mol Diagn* **8**, 528-533, doi:10.2353/jmoldx.2006.060029 (2006).
- 255 Iorio, F. *et al.* Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting. *BMC genomics* **19**, 604, doi:10.1186/s12864-018-4989-y (2018).

- 256 Oliveros, J. C. *Venny. An interactive tool for comparing lists with Venn's diagrams.* , <<https://bioinfogp.cnb.csic.es/tools/venny/index.html>> (2007-2015).
- 257 Qiu, Z., Oleinick, N. L. & Zhang, J. ATR/CHK1 inhibitors and cancer therapy. *Radiother Oncol* **126**, 450-464, doi:10.1016/j.radonc.2017.09.043 (2018).
- 258 Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* **47**, D607-d613, doi:10.1093/nar/gky1131 (2019).
- 259 Sato, E. *et al.* ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. *International journal of molecular sciences* **19**, doi:10.3390/ijms19061710 (2018).
- 260 Fouquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. *Pharmacol Res Perspect* **3**, e00149-e00149, doi:10.1002/prp2.149 (2015).
- 261 Meyers, R. M. *et al.* Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. *Nature genetics* **49**, 1779-1784, doi:10.1038/ng.3984 (2017).
- 262 Wilsker, D. *et al.* The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes. *Nucleic Acids Res* **32**, 1345-1353, doi:10.1093/nar/gkh277 (2004).
- 263 Flores-Alcantar, A., Gonzalez-Sandoval, A., Escalante-Alcalde, D. & Lomeli, H. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle. *Cell and tissue research* **345**, 137-148, doi:10.1007/s00441-011-1182-x (2011).
- 264 Kelso, T. W. R. *et al.* Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. *eLife* **6**, doi:10.7554/eLife.30506 (2017).
- 265 Trizzino, M. *et al.* The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. *Cell reports* **23**, 3933-3945, doi:10.1016/j.celrep.2018.05.097 (2018).
- 266 Raab, J. R., Resnick, S. & Magnuson, T. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes. *PLoS genetics* **11**, e1005748, doi:10.1371/journal.pgen.1005748 (2015).
- 267 Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128, doi:10.1186/1471-2105-14-128 (2013).
- 268 Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* **44**, W90-97, doi:10.1093/nar/gkw377 (2016).
- 269 Carette, J. E. *et al.* Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. *Nature* **477**, 340-343, doi:10.1038/nature10348 (2011).
- 270 Jang, J.-H. FIGC, a novel FGF-induced ubiquitin-protein ligase in gastric cancers. *FEBS Lett* **578**, 21-25, doi:10.1016/j.febslet.2004.10.071 (2004).
- 271 Beilke, S. *et al.* The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice. *Oncogene* **29**, 4058-4067, doi:10.1038/onc.2010.156 (2010).
- 272 Zou, J., Mi, L., Yu, X. F. & Dong, J. Interaction of 14-3-3sigma with KCMF1 suppresses the proliferation and colony formation of human colon cancer stem cells. *World journal of gastroenterology* **19**, 3770-3780, doi:10.3748/wjg.v19.i24.3770 (2013).
- 273 Mandegar, M. A. *et al.* CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. *Cell Stem Cell* **18**, 541-553, doi:10.1016/j.stem.2016.01.022 (2016).

- 274 Eskildsen, T. V. *et al.* MESP1 knock-down in human iPSC attenuates early vascular progenitor cell differentiation after completed primitive streak specification. *Developmental biology* **445**, 1-7, doi:10.1016/j.ydbio.2018.10.020 (2019).
- 275 Genga, R. M. J. *et al.* Single-Cell RNA-Sequencing-Based CRISPRi Screening Resolves Molecular Drivers of Early Human Endoderm Development. *Cell reports* **27**, 708-718.e710, doi:10.1016/j.celrep.2019.03.076 (2019).
- 276 Heman-Ackah, S. M., Bassett, A. R. & Wood, M. J. A. Precision Modulation of Neurodegenerative Disease-Related Gene Expression in Human iPSC-Derived Neurons. *Scientific reports* **6**, 28420-28420, doi:10.1038/srep28420 (2016).
- 277 Liu, S. J. *et al.* CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. *Science (New York, N.Y.)* **355**, aah7111, doi:10.1126/science.aah7111 (2017).
- 278 Luo, Y. *et al.* Targeted Inhibition of the miR-199a/214 Cluster by CRISPR Interference Augments the Tumor Tropism of Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells under Hypoxic Condition. *Stem cells international* **2016**, 3598542, doi:10.1155/2016/3598542 (2016).
- 279 Tian, R. *et al.* CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. *Neuron*, doi:10.1016/j.neuron.2019.07.014 (2019).
- 280 Downward, J. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? *Clinical cancer research : an official journal of the American Association for Cancer Research* **21**, 1802-1809, doi:10.1158/1078-0432.CCR-14-2180 (2015).
- 281 Chaffer, C. L. & Weinberg, R. A. A Perspective on Cancer Cell Metastasis. *Science* **331**, 1559-1564 (2011).
- 282 Liu, Q. *et al.* Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis. *Mol Cancer* **16**, 176-176, doi:10.1186/s12943-017-0742-4 (2017).
- 283 Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D. & Overwijk, W. W. The immune system in cancer metastasis: friend or foe? *Journal for ImmunoTherapy of Cancer* **5**, 79, doi:10.1186/s40425-017-0283-9 (2017).
- 284 Bubenik, J. Tumour MHC class I downregulation and immunotherapy (Review). *Oncology reports* **10**, 2005-2008 (2003).
- 285 Blomberg, O. S., Spagnuolo, L. & de Visser, K. E. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. *Disease models & mechanisms* **11**, doi:10.1242/dmm.036236 (2018).
- 286 Camerer, E. *et al.* Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. *Blood* **104**, 397-401, doi:10.1182/blood-2004-02-0434 (2004).
- 287 Palumbo, J. S. *et al.* Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood* **105**, 178-185, doi:10.1182/blood-2004-06-2272 (2005).
- 288 Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer cell* **20**, 576-590, doi:10.1016/j.ccr.2011.09.009 (2011).
- 289 Khanna, C. & Hunter, K. Modeling metastasis in vivo. *Carcinogenesis* **26**, 513-523, doi:10.1093/carcin/bgh261 (2005).
- 290 Fidler, I. J. Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2'-deoxyuridine. *JNCI: Journal of the National Cancer Institute* **45**, 773-782, doi:10.1093/jnci/45.4.773 (1970).
- 291 Fidler, I. J. Selection of Successive Tumour Lines for Metastasis. *Nature New Biology* **242**, 148-149, doi:10.1038/newbio242148a0 (1973).



- 292 Fidler, I. J. Biological Behavior of Malignant Melanoma Cells Correlated to Their Survival *in Vivo*. *Cancer Research* **35**, 218-224 (1975).
- 293 van der Weyden, L. *et al.* Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. *Nature* **541**, 233, doi:10.1038/nature20792 (2017).
- 294 Gumireddy, K. *et al.* KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. *Nature cell biology* **11**, 1297-1304, doi:10.1038/ncb1974 (2009).
- 295 Gumireddy, K. *et al.* In vivo selection for metastasis promoting genes in the mouse. *Proc Natl Acad Sci U S A* **104**, 6696-6701, doi:10.1073/pnas.0701145104 (2007).
- 296 Sasaki, K. *et al.* Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. *Clinical & experimental metastasis* **34**, 229-239, doi:10.1007/s10585-017-9840-3 (2017).
- 297 Katigbak, A. *et al.* A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. *Scientific reports* **6**, 38968, doi:10.1038/srep38968 (2016).
- 298 Kodama, M. *et al.* In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. *Proc Natl Acad Sci U S A* **114**, E7301-E7310, doi:10.1073/pnas.1705441114 (2017).
- 299 Manguso, R. T. *et al.* In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* **547**, 413-418, doi:10.1038/nature23270 (2017).
- 300 Chen, S. *et al.* Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. *Cell* **160**, 1246-1260, doi:10.1016/j.cell.2015.02.038 (2015).
- 301 Maeder, M. L. *et al.* CRISPR RNA-guided activation of endogenous human genes. *Nature Methods* **10**, 977, doi:10.1038/nmeth.2598 (2013).
- 302 Braun, C. J. *et al.* Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. *Proc Natl Acad Sci U S A* **113**, E3892-3900, doi:10.1073/pnas.1600582113 (2016).
- 303 Wangenstein, K. J. *et al.* Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. *Hepatology (Baltimore, Md.)* **68**, 663-676, doi:10.1002/hep.29626 (2018).
- 304 Zhou, H. *et al.* In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. *Nature neuroscience* **21**, 440-446, doi:10.1038/s41593-017-0060-6 (2018).
- 305 Horlbeck, M. A. *et al.* Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. *eLife* **5**, doi:10.7554/eLife.19760 (2016).
- 306 Chong, Z. S., Ohnishi, S., Yusa, K. & Wright, G. J. Pooled extracellular receptor-ligand interaction screening using CRISPR activation. *Genome Biol* **19**, 205, doi:10.1186/s13059-018-1581-3 (2018).
- 307 Wu, W., Baker, M. E., Eraly, S. A., Bush, K. T. & Nigam, S. K. Analysis of a large cluster of SLC22 transporter genes, including novel USTs, reveals species-specific amplification of subsets of family members. *Physiol Genomics* **38**, 116-124, doi:10.1152/physiolgenomics.90309.2008 (2009).
- 308 Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Molecular & cellular proteomics : MCP* **13**, 397-406, doi:10.1074/mcp.M113.035600 (2014).
- 309 Alper, S. L. Molecular physiology of SLC4 anion exchangers. *Experimental physiology* **91**, 153-161, doi:10.1113/expphysiol.2005.031765 (2006).
- 310 Sander, T. *et al.* Association of the 867Asp variant of the human anion exchanger 3 gene with common subtypes of idiopathic generalized epilepsy. *Epilepsy research* **51**, 249-255, doi:10.1016/s0920-1211(02)00152-3 (2002).

- 311 Wang, H. S., Chen, Y., Vairamani, K. & Shull, G. E. Critical role of bicarbonate and bicarbonate transporters in cardiac function. *World journal of biological chemistry* **5**, 334-345, doi:10.4331/wjbc.v5.i3.334 (2014).
- 312 Birnbaum, S. G. *et al.* Structure and function of Kv4-family transient potassium channels. *Physiol Rev* **84**, 803-833, doi:10.1152/physrev.00039.2003 (2004).
- 313 Chien, W. & Pei, L. A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. *The Journal of biological chemistry* **275**, 19422-19427, doi:10.1074/jbc.M910105199 (2000).
- 314 Watkins, R. J. *et al.* Pituitary tumor transforming gene binding factor: a new gene in breast cancer. *Cancer Res* **70**, 3739-3749, doi:10.1158/0008-5472.Can-09-3531 (2010).
- 315 Read, M. L. *et al.* The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. *Endocrinology* **155**, 1222-1234, doi:10.1210/en.2013-1646 (2014).
- 316 Read, M. L. *et al.* The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer. *Molecular carcinogenesis* **55**, 15-26, doi:10.1002/mc.22254 (2016).
- 317 Watkins, R. J. *et al.* Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin. *The Journal of clinical endocrinology and metabolism* **101**, 4551-4563, doi:10.1210/jc.2016-1932 (2016).
- 318 Glerup, S. *et al.* SorCS2 is required for BDNF-dependent plasticity in the hippocampus. *Molecular Psychiatry* **21**, 1740-1751, doi:10.1038/mp.2016.108 (2016).
- 319 Malik, A. R. *et al.* SorCS2 Controls Functional Expression of Amino Acid Transporter EAAT3 and Protects Neurons from Oxidative Stress and Epilepsy-Induced Pathology. *Cell reports* **26**, 2792-2804.e2796, doi:10.1016/j.celrep.2019.02.027 (2019).
- 320 Baum, A. E. *et al.* A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Mol Psychiatry* **13**, 197-207, doi:10.1038/sj.mp.4002012 (2008).
- 321 Christoforou, A. *et al.* Convergence of linkage, association and GWAS findings for a candidate region for bipolar disorder and schizophrenia on chromosome 4p. *Molecular Psychiatry* **16**, 240-242, doi:10.1038/mp.2010.25 (2011).
- 322 Goffinet, A. M. & Tissir, F. Seven pass Cadherins CELSR1-3. *Seminars in cell & developmental biology* **69**, 102-110, doi:10.1016/j.semcdb.2017.07.014 (2017).
- 323 Qiao, Z. *et al.* Mutations in KIAA1109, CACNA1C, BSN, AKAP13, CELSR2, and HELZ2 Are Associated With the Prognosis in Endometrial Cancer. *Front Genet* **10**, 909, doi:10.3389/fgene.2019.00909 (2019).
- 324 Roumeliotis, T. I. *et al.* Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. *Cell Rep* **20**, 2201-2214, doi:10.1016/j.celrep.2017.08.010 (2017).
- 325 Agu, C. A. *et al.* Successful Generation of Human Induced Pluripotent Stem Cell Lines from Blood Samples Held at Room Temperature for up to 48 hr. *Stem cell reports* **5**, 660-671, doi:10.1016/j.stemcr.2015.08.012 (2015).
- 326 Gonçalves, E. *et al.* Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. *Genome Biology* **20**, 27, doi:10.1186/s13059-019-1637-z (2019).